Galena Biopharma (GALE) 2.39 $GALE
Technical Coverage on Biotech Equities - Galena Biopharma, Gilead Sciences, MannKind, Orexigen Therapeutics, and IsoRay
PR Newswire - Wed Sep 03, 8:05AM CDT
The US markets on Tuesday, September 02, 2014 ended on a mixed note as the Dow Jones Industrial Average finished at 17,067.56, down 0.18% and the NASDAQ Composite closed at 4,598.19, up 0.39%. The S&P 500 finished the session 0.05% lower at 2,002.28. During the trading session, five out of ten sectors finished on a higher note. The S&P 500 Health Care Sector Index ended the day at 737.75, up 0.02%, with the index gaining 6.88% in the previous three months. Investor-Edge has initiated coverage on the following equities: Galena Biopharma Inc. (NASDAQ: GALE), Gilead Sciences Inc. (NASDAQ: GILD), MannKind Corporation (NASDAQ: MNKD), Orexigen Therapeutics Inc. (NASDAQ: OREX), and IsoRay Inc. (NYSE MKT: ISR). Free research on these five companies can be accessed at:
Galena Biopharma to Present at the Rodman & Renshaw 16th Annual Global Investment Conference
GlobeNewswire - Wed Sep 03, 6:05AM CDT
Galena Biopharma, Inc. (Nasdaq:GALE), a biopharmaceutical company developing and commercializing innovative, targeted oncology treatments that address major medical needs across the full spectrum of cancer care, today announced that Mark W. Schwartz, Ph.D., President and Chief Executive Officer will present a corporate update at the Rodman & Renshaw 16th Annual Global Investment Conference. The presentation will take place on Tuesday, September 9, 2014 at 2:55 p.m. ET at the New York Palace Hotel in New York, NY.
Global Peptide Cancer Therapeutics Market & Pipeline Insight 2014
M2 - Fri Aug 29, 3:25AM CDT
Research and Markets (http://www.researchandmarkets.com/research/gr3rvm/global_peptide) has announced the addition of the "Global Peptide Cancer Therapeutics Market & Pipeline Insight 2014" report to their offering. The conventional methods developed to prevent and eradicate the prevalence of cancer have achieved limited success in cancer treatment. These methods are confined to low specificity, safety and large number of side effects, which prompted the researchers to look for a better solution. It has been discovered that peptides can be used for effective and viable treatment of cancer without having disadvantages of conventional methods. The quintessential for using peptide cancer therapeutics is that they have high specificity, safety and efficacy which is not provide by therapeutics available in market. The completion of human genome sequencing has helped in the research and development of peptide cancer therapeutics. The data allowed the researchers to look deep into the root cause of cancer hidden in human genome. This has allowed targeting cancer cells with high accuracy; thus, increasing the probability of treatment with high success rates. Using this data several novel molecules are being developed, which will have higher stability, effective delivery and minimal or no side-effects. Peptide cancer therapeutics has edge in treating rare type of cancers. Conventional approaches of cancer treatments are unable to treat them successfully. Sometimes these approaches cannot be used due to unspecificity or they are not effective at all. For instance, brain cancer is a rare type of cancer that falls in this category. Key Topics Covered: 1. Introduction to Peptide Cancer Therapeutics 2. Mechanism of Peptide Cancer Therapeutics 3. Peptide Cancer Therapeutics Market Outlook 4. Peptide Cancer Therapeutics Market Dynamics 5. Peptide Cancer Therapeutics Market Future Growth Prospects 6. Peptide Cancer Drug Clinical Pipeline by Phase, Indication, Company & Country 7. Marketed Peptide Cancer Drug Insight by Indication, Country & Company 8. Suspended & Discontinued Peptide Cancer Drug in Clinical Trial by Phase, Indication, Company & Country 9. Competitive Landscape Companies Mentioned: - AngioChem - Antigen Express - Amgen - GlaxoSmithKline - Galena Biopharma - Ipsen - Merck - PeptiDream - Roche - Sanofi For more information visit http://www.researchandmarkets.com/research/gr...al_peptide
Commit To Buy Galena Biopharma At $1.50, Earn 36.7% Using Options
StockOptionsChannel.com - Thu Aug 28, 10:31AM CDT
Investors eyeing a purchase of Galena Biopharma Inc stock, but cautious about paying the going market price of $2.39/share, might benefit from considering selling puts among the alternative strategies at their disposal. One interesting put contract...
Why Galena Biopharma (GALE) Stock Is Spiking Today
at The Street - Wed Aug 27, 10:36AM CDT
Galena Biopharma (GALE) shares are up double digits after analysts at MLV & Co reiterated their 'buy' rating on the stock.
Galena Fires CEO Ahn, Offers No Parting Gifts
at The Street - Mon Aug 25, 7:48AM CDT
CEOs who leave companies on good terms get cushy severance packages. Galena's Ahn did not.
Biotech Stock Mailbag: Threshold, Galena, CytRx
at The Street - Fri Aug 22, 7:48AM CDT
Biotech columnist Adam Feuerstein answers readers' questions about health care.
Galena Biopharma elects Dr Mark W. Schwartz as CEO
M2 - Fri Aug 22, 6:17AM CDT
Biopharmaceutical company Galena Biopharma (NasdaqGS:GALE) said on Thursday that Dr Mark W. Schwartz, PhD has been promoted to president and chief executive officer and proposed to its board of directors.
Galena CEO Fired Following Stock-Promotions Scandal
at The Street - Thu Aug 21, 6:16AM CDT
Mark Ahn's forced exit from the troubled Galena follows an internal investigation by the board.
Galena Biopharma Appoints Mark W. Schwartz, Ph.D., as President and Chief Executive Officer
GlobeNewswire - Thu Aug 21, 6:12AM CDT
Galena Biopharma, Inc. (Nasdaq:GALE), a biopharmaceutical company developing and commercializing innovative, targeted oncology treatments that address major medical needs across the full spectrum of cancer care, today announced that Mark W. Schwartz, Ph.D., has been appointed as President and Chief Executive Officer, effective immediately. Dr. Schwartz was previously Galena's Executive Vice President and Chief Operating Officer. He replaces Mark J. Ahn, Ph.D. who has resigned as the President and CEO and as a director of the company to pursue other long held personal and professional goals. It is expected that Dr. Schwartz will also be appointed to Galena's Board of Directors.
Biotech Stock Mailbag: Exact Sciences, Galena, Amgen
at The Street - Fri Aug 15, 6:22AM CDT
Biotech columnist Adam Feuerstein answers readers' questions about health care.
Why Galena Biopharma Inc. Stock Tumbled
Sean Williams, The Motley Fool - Motley Fool - Tue Aug 12, 12:02PM CDT
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis. What: Shares of Galena Biopharma , a biopharmaceutical...
Intercept Pharma Soars On Positive Liver Drug Data
at Investor's Business Daily - Mon Aug 11, 9:20PM CDT
Intercept Pharmaceuticals (ICPT) released new data on its experimental fatty liver drug showing the treatment is effective and has less-severe side effects than previous feared, sending shares soaring 58% to 374 in late trading on the stock market...
Galena Biopharma Reports Second Quarter 2014 Results
GlobeNewswire - Mon Aug 11, 3:35PM CDT
-- Abstral(R) (fentanyl) sublingual tablet net revenue was $2.3 million in Q2 2014 and $4.5 million in 1H 2014.
Biotech Stocks Technical Data -- MannKind, ARIAD Pharma, Galena Biopharma, Geron, and Peregrine Pharma
PR Newswire - Fri Aug 01, 8:00AM CDT
On Thursday, July 31, 2014, the NASDAQ Composite ended at 4,369.77, down 2.09%, the Dow Jones Industrial Average finished the day 1.88% lower at 16,563.30, and the S&P 500 closed at 1,930.67, down 2.00%. The losses were broad based as all the ten sectors ended the session in negative. The S&P 500 Health Care Sector Index ended the day at 704.37, down 2.03%, and the index has declined 0.02% in the last one month. Investor-Edge has initiated coverage on the following equities: MannKind Corporation (NASDAQ: MNKD), ARIAD Pharmaceuticals Inc. (NASDAQ: ARIA), Galena Biopharma Inc. (NASDAQ: GALE), Geron Corporation(NASDAQ: GERN), and Peregrine Pharmaceuticals Inc. (NASDAQ: PPHM). Free research on these five companies can be accessed at:
Galena Biopharma to Report Second Quarter 2014 Financial Results on Monday, August 11, 2014
GlobeNewswire - Tue Jul 29, 6:40AM CDT
Galena Biopharma, Inc. (Nasdaq:GALE), a biopharmaceutical company developing and commercializing innovative, targeted oncology treatments that address major unmet medical needs to advance cancer care, today announced that the Company will report its second quarter financial results on Monday, August 11, 2014 after the close of the financial markets. The company will host a conference call following the announcement at 2:00 p.m. P.T./5:00 pm E.T. to discuss financial and business results.
Galectin Pays Stock Promoters to Entice Retail Investors
at The Street - Mon Jul 28, 11:34AM CDT
Like Galena BioPharma and The DreamTeam Group, Galectin is also paying for a promotional campaign designed to entice retail investors into buying its stock.
Galena Biopharma, Inc. - Product Pipeline Review - 2014
M2 - Fri Jul 25, 3:37AM CDT
Summary
Galena Stock: What to Watch for
Michael Douglass and David Williamson, The Motley Fool - Motley Fool - Tue Jul 22, 3:20PM CDT
Galena Biopharma announced this morning that it has licensed the rights to sell Zuplenz for $5 million in stock and cash, in addition to royalties, milestones, and an upfront payment. Galena investors: There are some more important things to...
Technical Coverage on Biotech Equities - Galena Biopharma, Gilead Sciences, MannKind, Orexigen Therapeutics, and IsoRay
PR Newswire - Wed Sep 03, 8:05AM CDT
The US markets on Tuesday, September 02, 2014 ended on a mixed note as the Dow Jones Industrial Average finished at 17,067.56, down 0.18% and the NASDAQ Composite closed at 4,598.19, up 0.39%. The S&P 500 finished the session 0.05% lower at 2,002.28. During the trading session, five out of ten sectors finished on a higher note. The S&P 500 Health Care Sector Index ended the day at 737.75, up 0.02%, with the index gaining 6.88% in the previous three months. Investor-Edge has initiated coverage on the following equities: Galena Biopharma Inc. (NASDAQ: GALE), Gilead Sciences Inc. (NASDAQ: GILD), MannKind Corporation (NASDAQ: MNKD), Orexigen Therapeutics Inc. (NASDAQ: OREX), and IsoRay Inc. (NYSE MKT: ISR). Free research on these five companies can be accessed at:
Galena Biopharma to Present at the Rodman & Renshaw 16th Annual Global Investment Conference
GlobeNewswire - Wed Sep 03, 6:05AM CDT
Galena Biopharma, Inc. (Nasdaq:GALE), a biopharmaceutical company developing and commercializing innovative, targeted oncology treatments that address major medical needs across the full spectrum of cancer care, today announced that Mark W. Schwartz, Ph.D., President and Chief Executive Officer will present a corporate update at the Rodman & Renshaw 16th Annual Global Investment Conference. The presentation will take place on Tuesday, September 9, 2014 at 2:55 p.m. ET at the New York Palace Hotel in New York, NY.
Global Peptide Cancer Therapeutics Market & Pipeline Insight 2014
M2 - Fri Aug 29, 3:25AM CDT
Research and Markets (http://www.researchandmarkets.com/research/gr3rvm/global_peptide) has announced the addition of the "Global Peptide Cancer Therapeutics Market & Pipeline Insight 2014" report to their offering. The conventional methods developed to prevent and eradicate the prevalence of cancer have achieved limited success in cancer treatment. These methods are confined to low specificity, safety and large number of side effects, which prompted the researchers to look for a better solution. It has been discovered that peptides can be used for effective and viable treatment of cancer without having disadvantages of conventional methods. The quintessential for using peptide cancer therapeutics is that they have high specificity, safety and efficacy which is not provide by therapeutics available in market. The completion of human genome sequencing has helped in the research and development of peptide cancer therapeutics. The data allowed the researchers to look deep into the root cause of cancer hidden in human genome. This has allowed targeting cancer cells with high accuracy; thus, increasing the probability of treatment with high success rates. Using this data several novel molecules are being developed, which will have higher stability, effective delivery and minimal or no side-effects. Peptide cancer therapeutics has edge in treating rare type of cancers. Conventional approaches of cancer treatments are unable to treat them successfully. Sometimes these approaches cannot be used due to unspecificity or they are not effective at all. For instance, brain cancer is a rare type of cancer that falls in this category. Key Topics Covered: 1. Introduction to Peptide Cancer Therapeutics 2. Mechanism of Peptide Cancer Therapeutics 3. Peptide Cancer Therapeutics Market Outlook 4. Peptide Cancer Therapeutics Market Dynamics 5. Peptide Cancer Therapeutics Market Future Growth Prospects 6. Peptide Cancer Drug Clinical Pipeline by Phase, Indication, Company & Country 7. Marketed Peptide Cancer Drug Insight by Indication, Country & Company 8. Suspended & Discontinued Peptide Cancer Drug in Clinical Trial by Phase, Indication, Company & Country 9. Competitive Landscape Companies Mentioned: - AngioChem - Antigen Express - Amgen - GlaxoSmithKline - Galena Biopharma - Ipsen - Merck - PeptiDream - Roche - Sanofi For more information visit http://www.researchandmarkets.com/research/gr...al_peptide
Commit To Buy Galena Biopharma At $1.50, Earn 36.7% Using Options
StockOptionsChannel.com - Thu Aug 28, 10:31AM CDT
Investors eyeing a purchase of Galena Biopharma Inc stock, but cautious about paying the going market price of $2.39/share, might benefit from considering selling puts among the alternative strategies at their disposal. One interesting put contract...
Why Galena Biopharma (GALE) Stock Is Spiking Today
at The Street - Wed Aug 27, 10:36AM CDT
Galena Biopharma (GALE) shares are up double digits after analysts at MLV & Co reiterated their 'buy' rating on the stock.
Galena Fires CEO Ahn, Offers No Parting Gifts
at The Street - Mon Aug 25, 7:48AM CDT
CEOs who leave companies on good terms get cushy severance packages. Galena's Ahn did not.
Biotech Stock Mailbag: Threshold, Galena, CytRx
at The Street - Fri Aug 22, 7:48AM CDT
Biotech columnist Adam Feuerstein answers readers' questions about health care.
Galena Biopharma elects Dr Mark W. Schwartz as CEO
M2 - Fri Aug 22, 6:17AM CDT
Biopharmaceutical company Galena Biopharma (NasdaqGS:GALE) said on Thursday that Dr Mark W. Schwartz, PhD has been promoted to president and chief executive officer and proposed to its board of directors.
Galena CEO Fired Following Stock-Promotions Scandal
at The Street - Thu Aug 21, 6:16AM CDT
Mark Ahn's forced exit from the troubled Galena follows an internal investigation by the board.
Galena Biopharma Appoints Mark W. Schwartz, Ph.D., as President and Chief Executive Officer
GlobeNewswire - Thu Aug 21, 6:12AM CDT
Galena Biopharma, Inc. (Nasdaq:GALE), a biopharmaceutical company developing and commercializing innovative, targeted oncology treatments that address major medical needs across the full spectrum of cancer care, today announced that Mark W. Schwartz, Ph.D., has been appointed as President and Chief Executive Officer, effective immediately. Dr. Schwartz was previously Galena's Executive Vice President and Chief Operating Officer. He replaces Mark J. Ahn, Ph.D. who has resigned as the President and CEO and as a director of the company to pursue other long held personal and professional goals. It is expected that Dr. Schwartz will also be appointed to Galena's Board of Directors.
Biotech Stock Mailbag: Exact Sciences, Galena, Amgen
at The Street - Fri Aug 15, 6:22AM CDT
Biotech columnist Adam Feuerstein answers readers' questions about health care.
Why Galena Biopharma Inc. Stock Tumbled
Sean Williams, The Motley Fool - Motley Fool - Tue Aug 12, 12:02PM CDT
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis. What: Shares of Galena Biopharma , a biopharmaceutical...
Intercept Pharma Soars On Positive Liver Drug Data
at Investor's Business Daily - Mon Aug 11, 9:20PM CDT
Intercept Pharmaceuticals (ICPT) released new data on its experimental fatty liver drug showing the treatment is effective and has less-severe side effects than previous feared, sending shares soaring 58% to 374 in late trading on the stock market...
Galena Biopharma Reports Second Quarter 2014 Results
GlobeNewswire - Mon Aug 11, 3:35PM CDT
-- Abstral(R) (fentanyl) sublingual tablet net revenue was $2.3 million in Q2 2014 and $4.5 million in 1H 2014.
Biotech Stocks Technical Data -- MannKind, ARIAD Pharma, Galena Biopharma, Geron, and Peregrine Pharma
PR Newswire - Fri Aug 01, 8:00AM CDT
On Thursday, July 31, 2014, the NASDAQ Composite ended at 4,369.77, down 2.09%, the Dow Jones Industrial Average finished the day 1.88% lower at 16,563.30, and the S&P 500 closed at 1,930.67, down 2.00%. The losses were broad based as all the ten sectors ended the session in negative. The S&P 500 Health Care Sector Index ended the day at 704.37, down 2.03%, and the index has declined 0.02% in the last one month. Investor-Edge has initiated coverage on the following equities: MannKind Corporation (NASDAQ: MNKD), ARIAD Pharmaceuticals Inc. (NASDAQ: ARIA), Galena Biopharma Inc. (NASDAQ: GALE), Geron Corporation(NASDAQ: GERN), and Peregrine Pharmaceuticals Inc. (NASDAQ: PPHM). Free research on these five companies can be accessed at:
Galena Biopharma to Report Second Quarter 2014 Financial Results on Monday, August 11, 2014
GlobeNewswire - Tue Jul 29, 6:40AM CDT
Galena Biopharma, Inc. (Nasdaq:GALE), a biopharmaceutical company developing and commercializing innovative, targeted oncology treatments that address major unmet medical needs to advance cancer care, today announced that the Company will report its second quarter financial results on Monday, August 11, 2014 after the close of the financial markets. The company will host a conference call following the announcement at 2:00 p.m. P.T./5:00 pm E.T. to discuss financial and business results.
Galectin Pays Stock Promoters to Entice Retail Investors
at The Street - Mon Jul 28, 11:34AM CDT
Like Galena BioPharma and The DreamTeam Group, Galectin is also paying for a promotional campaign designed to entice retail investors into buying its stock.
Galena Biopharma, Inc. - Product Pipeline Review - 2014
M2 - Fri Jul 25, 3:37AM CDT
Summary
Galena Stock: What to Watch for
Michael Douglass and David Williamson, The Motley Fool - Motley Fool - Tue Jul 22, 3:20PM CDT
Galena Biopharma announced this morning that it has licensed the rights to sell Zuplenz for $5 million in stock and cash, in addition to royalties, milestones, and an upfront payment. Galena investors: There are some more important things to...
